右美托咪定作为酒精戒断谵妄治疗的辅助药物：一例病例报告。
Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report.
作者信息
Rovasalo Aki, Tohmo Harri, Aantaa Riku, Kettunen Eija, Palojoki Riitta
机构信息
Hospital District of Helsinki and Uusimaa, Hyvinkää Hospital, Hyvinkää, Finland.
出版信息
Gen Hosp Psychiatry. 2006 Jul-Aug;28(4):362-3. doi: 10.1016/j.genhosppsych.2006.03.002.
In this case report, even a moderate dose of dexmedetomidine, a very selective alpha(2)-adrenergic agent, resulted in a rapid response to alcohol withdrawal delirium after the standard treatment. Psychiatrists should be aware of this relatively new drug that provides advantages over clonidine, heavy sedation and secondary restraints. Dexmedetomidine should be further evaluated in the treatment of specific forms of aggressive behavior and complicated withdrawal states.
在本病例报告中，即使是中等剂量的右美托咪定（一种非常有选择性的α₂肾上腺素能药物），在标准治疗后也能对酒精戒断谵妄产生快速反应。精神科医生应了解这种相对较新的药物，它比可乐定、深度镇静和二级约束具有优势。右美托咪定应在特定形式的攻击性行为和复杂戒断状态的治疗中进一步评估。
Zotero 插件